; or (ii) has been included on the list under section 506E. (B) The fees pursuant to section 744B(a)(3) shall be waived with respect to an application described in subparagraph (A), unless such application contains a certification under paragraph (2)(A)(vii)(IV). (C) The Secretary may expedite an inspection or reinspection under section 704 of an establishment that proposes to manufacture a drug described in subparagraph (A). . 102. Reporting on pending generic drug applications Not later than 90 calendar days after the date of enactment of this Act, and every 90 calendar days thereafter until October 1, 2022, the Secretary of Health and Human Services shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate, the Special Committee on Aging of the Senate, and the Committee on Energy and Commerce of the House of Representatives a report that provides— (1) the number of applications that were filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ) prior to October 1, 2015, that are pending at the time the report is submitted; (2) the average and median total time such applications have been pending; (3) the number of such applications that contain certifications under section 505(j)(2)(A)(vii)(IV) of such Act